PURPOSE: The purpose of this study was to develop a molecular imaging technique using tracers specific for ductal carcinoma in situ (DCIS) to improve visualization and localization of DCIS during surgery. As CD44v6 is frequently expressed in DCIS, we used near-infrared fluorescently labeled CD44v6-targeting antibodies for detection of DCIS. PROCEDURE: Mice bearing orthotopically transplanted CD44v6-positive MCF10DCIS DCIS-like tumors and CD44v6-negative MDA-MB-231 control tumors were intravenously injected with IRDye800CW conjugated to CD44v6-specific antibodies or control IgGs. Noninvasive imaging was performed for 8 days postinjection, followed by intraoperative imaging. Antibody accumulation and intratumor distribution were examined. RESULTS: Maximum accumulation of CD44v6-specific antibodies was obtained 24 h postinjection. Maximum tumor-to-background ratio for MCF10DCIS tumors was 4.5 ± 0.2, compared to 1.4 ± 0.1 (control tumors, p = 0.006), and 1.7 ± 0.1 (control IgG, p = 0.014), for 8 days postinjection. Ex vivo, tumor-to-background ratios were comparable to those obtained by intraoperative imaging. CONCLUSIONS: We show the applicability of noninvasive and intraoperative optical imaging of DCIS-like lesions in vivo using CD44v6-specific antibodies.
PURPOSE: The purpose of this study was to develop a molecular imaging technique using tracers specific for ductal carcinoma in situ (DCIS) to improve visualization and localization of DCIS during surgery. As CD44v6 is frequently expressed in DCIS, we used near-infrared fluorescently labeled CD44v6-targeting antibodies for detection of DCIS. PROCEDURE: Mice bearing orthotopically transplanted CD44v6-positive MCF10DCIS DCIS-like tumors and CD44v6-negative MDA-MB-231 control tumors were intravenously injected with IRDye800CW conjugated to CD44v6-specific antibodies or control IgGs. Noninvasive imaging was performed for 8 days postinjection, followed by intraoperative imaging. Antibody accumulation and intratumor distribution were examined. RESULTS: Maximum accumulation of CD44v6-specific antibodies was obtained 24 h postinjection. Maximum tumor-to-background ratio for MCF10DCIS tumors was 4.5 ± 0.2, compared to 1.4 ± 0.1 (control tumors, p = 0.006), and 1.7 ± 0.1 (control IgG, p = 0.014), for 8 days postinjection. Ex vivo, tumor-to-background ratios were comparable to those obtained by intraoperative imaging. CONCLUSIONS: We show the applicability of noninvasive and intraoperative optical imaging of DCIS-like lesions in vivo using CD44v6-specific antibodies.
Authors: Véronique Orian-Rousseau; Linfeng Chen; Jonathan P Sleeman; Peter Herrlich; Helmut Ponta Journal: Genes Dev Date: 2002-12-01 Impact factor: 11.361
Authors: Christoph Hirche; Dawid Murawa; Zarah Mohr; Soeren Kneif; Michael Hünerbein Journal: Breast Cancer Res Treat Date: 2010-02-07 Impact factor: 4.872
Authors: Alexander B Stillebroer; Catharina M L Zegers; Otto C Boerman; Egbert Oosterwijk; Peter F A Mulders; Joseph A O'Donoghue; Eric P Visser; Wim J G Oyen Journal: J Nucl Med Date: 2011-12-12 Impact factor: 10.057
Authors: J A Foekens; P Dall; J G Klijn; P Skroch-Angel; C J Claassen; M P Look; H Ponta; W L Van Putten; P Herrlich; S C Henzen-Logmans Journal: Int J Cancer Date: 1999-06-21 Impact factor: 7.396
Authors: T H Oude Munnink; W B Nagengast; A H Brouwers; C P Schröder; G A Hospers; M N Lub-de Hooge; E van der Wall; P J van Diest; E G E de Vries Journal: Breast Date: 2009-10 Impact factor: 4.380
Authors: David R Colnot; Jan C Roos; Remco de Bree; Abraham J Wilhelm; J Alain Kummer; Gertraud Hanft; Karl-Heinz Heider; Gerd Stehle; Gordon B Snow; Guus A M S van Dongen Journal: Cancer Immunol Immunother Date: 2003-09 Impact factor: 6.968
Authors: Jeroen F Vermeulen; Aram S A van Brussel; Petra van der Groep; Folkert H M Morsink; Peter Bult; Elsken van der Wall; Paul J van Diest Journal: BMC Cancer Date: 2012-06-13 Impact factor: 4.430
Authors: Melissa L Korb; Yolanda E Hartman; Joy Kovar; Kurt R Zinn; Kirby I Bland; Eben L Rosenthal Journal: J Surg Res Date: 2013-11-22 Impact factor: 2.192